Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel

Supportive Care in Cancer

Volumn 7, Issue 4, 1999, Pages 260-264

  Gilad, Jacob ^a   Riesenberg, Klaris ^a   Mermershtain, Wilmosh ^a   Borer, Abraham ^a   Porath, Avi ^a   Schlaeffer, Francise ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Febrile neutropenia; G CSF; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; FEBRILE NEUTROPENIA; FEMALE; HUMAN; ISRAEL; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033044771     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050258     Document Type: Article

References (19)

1. American Society for Clinical Oncology(1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508
2. American Society for Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960
3. Bennett CL, Smith TJ, Weeks JC, et al (1996) Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology Survey. J Clin Oncol 14:2511-2520
4. Boogaerts MA, Demuynck HM (1996) Consensus on the clinical use of myeloid growth factors. Curr Opin Hematol 3:241-246
5. Bow EJ (1998) Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 41[Suppl D]:1-5
6. Chanock SJ (1993) Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 7:771-793
7. Chanock SJ, Pizzo PA (1996) Fever in the neutropenic host. Infect Dis Clin North Am 10:777-796
8. Crawford J, Ozer H, Stoller R, et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-metHuG-CSF). N Engl J Med 325:164-170
9. Faulds D, Lewis NJW, Milne RJ (1992) Recombinant granulocyte colony- stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia. Pharmacoeconomics 1:231-249
10. Gebbia V, Testa A, Valenza R, et al (1993) A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother 5:186-190
11. Hartmann LC, Tschetter LK, Habermann TM, et al (1997) Granulocyte-colony stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776-1780
12. Klasterski J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41 [Suppl D]:13-24
13. Lehrnbecher T, Chanock SJ (1998) Controversies in the treatment of neutropenia in cancer patients. Curr Opin Hematol 5:26-32
14. Lyman GH, Lyman CG, Sanderson RA, Balducci L (1993) Decision analysis of hematopoietic growth factors in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493
15. Nemunaitis J (1997) A comparative review of colony-stimulating factors. Drugs 54:709-729
16. Pettengell R, Gurney H, Radford JA, et al (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80:1430-1436
17. Pizzo PA (1989) Evaluation of fever in the patient with cancer. Eur J Cancer Clin Oncol 25 [Suppl 2]:S9-16
18. Smith TJ (1996) Economic analysis of the uses of the colony-stimulating factors. Curr Opin Hematol 3:175-179
19. Trillet-Lenoir V, Green J, Manegold C, et al (1993) Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer [A] 29:319-324